Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRAS(G12C)

Special oncogenic mutations in the RAS proteins lead to the aberrant activation of RAS and its downstream signaling pathways. AMG510, the first approval drug for KRAS, covalently binds to the mutated cysteine 12 of KRAS(G12C) protein and has shown promising antitumor activity in clinical trials. Rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuang, Haiming, Fan, Jigang, Li, Mingyu, Zhang, Hao, Yang, Xiuyan, Lin, Ligen, Lu, Shaoyong, Wang, Qing, Liu, Yaqin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399772/
https://www.ncbi.nlm.nih.gov/pubmed/36033504
http://dx.doi.org/10.3389/fonc.2022.915512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399772/
https://www.ncbi.nlm.nih.gov/pubmed/36033504
http://dx.doi.org/10.3389/fonc.2022.915512

Ejemplares similares